Gland PharmaNSE:GLAND -0.49%83 Net Margin % is 21.04% as of Mar. 2026, which is 3% below its 10-year median of 21.74. GuruFocus rates NSE:GLAND with a GF Score™ of 83/100 and a GF Value™ of ₹2,125.65 (Fairly Valued). The stock has 6 warning signs investors should review. Among 956 Drug Manufacturers companies, Gland Pharma ranks better than 81.17% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Gland Pharma's Net Income for the
three
months ended in Mar. 2026 was ₹3,667 Mil. Gland Pharma's Revenue for the
three
months ended in Mar. 2026 was ₹17,428 Mil. Therefore, Gland Pharma's net margin for the quarter that ended in Mar. 2026 was 21.04%.
The historical rank and industry rank for Gland Pharma's Net Margin % or its related term are showing as below:
NSE:GLAND'
s Net Margin % Range Over the Past 10 Years
Min: 12.44 Med: 21.74 Max: 30.05
Current: 15.98
NSE:GLAND's Net Margin % is ranked better than 81.17% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs NSE:GLAND: 15.98
Gland Pharma (NSE:GLAND) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Gland Pharma Net Margin % Related Terms
Gland Pharma Net Margin % Historical Data
* Premium members only.
The historical data trend for Gland Pharma's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gland Pharma Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's Net Margin % distribution charts can be found below:
* The bar in red indicates where Gland Pharma's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gland Pharma (NSE:GLAND) has a Net Margin % of 21.04% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Gland Pharma and its competitors. This is near median its historical median of 21.74. Over the past decade, Gland Pharma's Net Margin % has ranged from 12.44 to 30.05. According to the industry distribution chart, Gland Pharma ranks #180 out of 956 companies in the Drug Manufacturers industry, placing it in the top 18.8%.
Is Gland Pharma's Net Margin % too high?
Gland Pharma's current Net Margin % of 21.04% is near median its 10-year median of 21.74. Over the past 10 years, this metric has ranged from a low of 12.44 to a high of 30.05. The Drug Manufacturers industry median Net Margin % is 5.56. Gland Pharma's value of 21.04% is 278.4% above this industry median. Based on the distribution chart, Gland Pharma ranks #180 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Gland Pharma has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Gland Pharma ranks #180 out of 956 companies for Net Margin %. This places Gland Pharma in the top 19% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. Gland Pharma's value of 21.04% is 278.4% above this benchmark. Historically, Gland Pharma's own Net Margin % has ranged from 12.44 to 30.05 over the past decade. While the company's 10-year median is 21.74 vs. the industry median of 5.56, Gland Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gland Pharma's current Net Margin % of 21.04% is 278.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Gland Pharma and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gland Pharma's current Net Margin % is 21.04%, which is near median its own 10-year median of 21.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,125.65, compared to a current price of ₹2,314.80 — trading 8.9% above its estimated fair value. The current Net Margin % is 21.04%, which is near median its 10-year median of 21.74 and 278.4% above the Drug Manufacturers industry median of 5.56. Gland Pharma's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current Net Margin % is 21.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gland Pharma (NSE:GLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued.
The current stock price of ₹2,314.80 is trading 8.9% above its estimated GF Value™ of ₹2,125.65.
GuruFocus considers Gland Pharma to be Fairly Valued.
Key valuation signals for NSE:GLAND:
Net Margin %: 21.04% (near median its 10-year median of 21.74)
GF Value™: ₹2,125.65 vs. price of ₹2,314.80 (8.9% above fair value)
Industry Position: 278.4% above the Drug Manufacturers median (#180 of 956)
No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
83GF Score
Get the complete analysis for NSE:GLAND
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAND has been successfully added to your 
